Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease (Cochrane Review)

University of Tasmania, Medicine, GPO Box 252-34, Hobart, Tasmania, Australia.
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 02/2006; DOI: 10.1002/14651858.CD001390.pub2
Source: PubMed


As chronic obstructive pulmonary disease (COPD) progresses, exacerbations can occur with increasing frequency. One goal of therapy in COPD is to try and prevent these exacerbations, thereby reducing disease morbidity and associated healthcare costs. Pneumococcal vaccinations are considered to be one strategy for reducing the risk of infective exacerbations.
To determine the safety and efficacy of pneumococcal vaccination in COPD. The primary outcome assessed was acute exacerbations. Secondary outcomes of interest included episodes of pneumonia, hospital admissions, adverse events related to treatment, disability, change in lung function, mortality, and cost effectiveness.
We searched the Cochrane Airways Group COPD trials register using pre-specified terms. We also conducted additional handsearches of conference abstracts. The last round of searches were performed in April 2006.
Only randomised controlled trials assessing the effects of injectable pneumococcal vaccine in people with COPD were included.
Two review authors independently extracted data and three review authors independently assessed trial quality.
Although 10 studies cited in 11 publications were identified that met the inclusion criteria for this review, only four of these provided data on participants with COPD. The studies which did provide data for this review consisted of two trials using a 14-valent vaccine, and two using a 23-valent injectable vaccine. Data for the primary outcome, acute exacerbation of COPD, was available from only one of the four studies. The odds ratio of 1.43 (95% confidence interval (CI) 0.31 to 6.69) between interventions was not statistically significant. Of the secondary outcomes for which data were available and could be extracted, none reached statistical significance. Three studies provided dichotomous data for persons who developed pneumonia (OR 0.89, 95% CI 0.58 to 1.37, n = 748). Rates of hospital admissions and emergency department visits came from a single study. There was no significant reduction in the odds of all-cause mortality 1 to 48 months post-vaccination (Peto odds ratio 0.94, 95% CI 0.67 to 1.33, n = 888), or for death from cardiorespiratory causes (OR 1.07, 95% CI 0.69 to 1.66).
There is no evidence from randomised controlled trials that injectable pneumococcal vaccination in persons with COPD has a significant impact on morbidity or mortality. Further large randomised controlled trials would be needed to ascertain if the small benefits suggested by individual studies are real.

Download full-text


Available from: Punam Mangtani
  • [Show abstract] [Hide abstract]
    ABSTRACT: In many countries vaccination for the protection against infection of the bacteria pneumococcus, is part of the immunisation schedule for infants as well as, for people with bronchiectasis. In this review, our search for randomised control trials that examined the effectiveness of pneumococcal vaccines for people with bronchiectasis revealed no relevant studies. We thus cannot draw any conclusions for, or against, the routine pneumococcal vaccinations in people with bronchiectasis. However, we would recommend that national guidelines be followed until further evidence is available.
    No preview · Article · Feb 2007 · Cochrane database of systematic reviews (Online)
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic bronchitis (CB) is a disorder that is characterised by chronic mucus production. This disorder is called chronic obstructive pulmonary disease (COPD) when airflow obstruction is present. The majority of patients with COPD, which often goes undiagnosed or inadequately treated in the elderly, have symptoms consistent with CB. The clinical course of CB is usually punctuated by periodic acute exacerbations linked to infections caused by viral and typical or atypical bacterial pathogens. Acute exacerbations of chronic bronchitis (AECB) often lead to a decline in lung function and poor quality of life in association with increased risk of mortality and a significant economic impact on the healthcare system and society because of the direct costs of hospitalisations. In elderly individuals with COPD, co-morbidities play a vital role as determinants of health status and prognosis. Failure to eradicate infecting pathogens contributes to persistence of infection and inflammation that requires repeated courses of therapy and hospitalisation. Stratifying patients with AECB according to symptoms, degree of pulmonary function impairment and risk factors for poor outcome can help clinicians choose empirical antimicrobial chemotherapy regimens that are most likely to result in treatment success. Failure to cover likely pathogens associated with episodes of AECB can lead to lengthy hospital admissions and significant declines in functional status for elderly patients. Fluoroquinolones may provide the best therapeutic option for elderly patients with COPD who have complicated underlying CB but who are sufficiently stable to be treated in the outpatient setting. Optimised treatment for stable outpatients with CB may diminish the frequency of AECB, and effective antimicrobial therapy for AECB episodes can significantly diminish healthcare costs and maintain quality of life in the elderly patient.
    No preview · Article · Feb 2007 · Drugs & Aging
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients who suffer from chronic obstructive pulmonary disease (COPD) often experience acute exacerbations, which frequently require hospitalization and lead to increased mortality. The most common causes of exacerbation are viruses, bacteria, and air pollutants. The risk of influenza and pneumococcal-related hospitalization and death has been shown to be high among COPD sufferers of all ages.Influenza vaccination has shown itself to be effective in reducing morbidity and mortality in patients with underlying chronic respiratory diseases. Pneumococcal vaccine is effective in reducing the incidence of invasive disease. Therefore, COPD sufferers are a target group to be vaccinated against influenza and pneumococcus.Several coverage studies have identified non-compliant subjects and factors associated with influenza and pneumococcal vaccination recommendations. Age-based strategies have proved better than vaccinating high-risk-specific groups. Joint administration of influenza and pneumococcal vaccination has shown beneficial additive effects. Notwithstanding, implementation of some other strategies are needed to improve coverage.
    No preview · Article · Aug 2007 · Respiratory Medicine COPD Update
Show more